August Campaign Highlights Total Wellness for Over 8 Million in the U.S. with Psoriasis ALEXANDRIA, VA, UNITED STATES, August 1, 2025 /EINPres ...

With new systemic treatments now available for psoriatic disease, questions remain on the comparable efficacy and safety of these therapies.

Mentoring those newly diagnosed with psoriasis reminds a self-described old-timer of the value of lifestyle, community, and testing one’s limits.

Tildrakizumab is an interleukin-23 antagonist approved under the brand name Ilumya for the treatment of plaque psoriasis.

Q2 2025 Earnings Call Transcript July 31, 2025 AbbVie Inc. beats earnings expectations. Reported EPS is $2.97, expectations ...

Lower muscle volume, and more fat stored in the muscle, are seen linked to higher risk for disease and comorbidities.

UCB emerged as a major biopharmaceutical player in the 1990s with the development of blockbuster drugs Zyrtec and Keppra. Throughout the 1990s and early 2000s, UCB transformed from a hybrid ...